CN1204893C - 药物组合物 - Google Patents

药物组合物 Download PDF

Info

Publication number
CN1204893C
CN1204893C CNB998081574A CN99808157A CN1204893C CN 1204893 C CN1204893 C CN 1204893C CN B998081574 A CNB998081574 A CN B998081574A CN 99808157 A CN99808157 A CN 99808157A CN 1204893 C CN1204893 C CN 1204893C
Authority
CN
China
Prior art keywords
vitamin
pharmaceutical composition
oil
lipiodol
concentration
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CNB998081574A
Other languages
English (en)
Chinese (zh)
Other versions
CN1332629A (zh
Inventor
戴维·莫里斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
MRC HOLDING CO Ltd
Original Assignee
MRC HOLDING CO Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by MRC HOLDING CO Ltd filed Critical MRC HOLDING CO Ltd
Publication of CN1332629A publication Critical patent/CN1332629A/zh
Application granted granted Critical
Publication of CN1204893C publication Critical patent/CN1204893C/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CNB998081574A 1998-05-04 1999-05-04 药物组合物 Expired - Fee Related CN1204893C (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AUPP3328A AUPP332898A0 (en) 1998-05-04 1998-05-04 Pharmaceutical composition
AUPP3328 1998-05-04

Publications (2)

Publication Number Publication Date
CN1332629A CN1332629A (zh) 2002-01-23
CN1204893C true CN1204893C (zh) 2005-06-08

Family

ID=3807582

Family Applications (1)

Application Number Title Priority Date Filing Date
CNB998081574A Expired - Fee Related CN1204893C (zh) 1998-05-04 1999-05-04 药物组合物

Country Status (9)

Country Link
US (1) US6664246B2 (enExample)
EP (1) EP1124557A4 (enExample)
JP (1) JP2002513733A (enExample)
KR (1) KR20010052305A (enExample)
CN (1) CN1204893C (enExample)
AU (1) AUPP332898A0 (enExample)
HK (1) HK1044117B (enExample)
WO (1) WO1999056697A2 (enExample)
ZA (1) ZA200006953B (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6087350A (en) 1997-08-29 2000-07-11 University Of Pittsburgh Of The Commonwealth System Of Higher Education Use of pretreatment chemicals to enhance efficacy of cytotoxic agents
US7129230B2 (en) * 2001-03-12 2006-10-31 Nestec S.A. Method and product for treating cancer in pets
US20050038022A1 (en) * 2001-03-26 2005-02-17 Unisearch Limited Method for treatment of cancer and compositions for use therein
AUPR644301A0 (en) * 2001-07-17 2001-08-09 Unisearch Limited Method and composition for treatment of cancer
US20050209551A1 (en) * 2004-03-18 2005-09-22 Takemoto Arnold C Detoxification and breast health preparations
CA2558202A1 (en) * 2006-09-14 2006-11-23 Reinhold W. Vieth Vitamin d compositions and method of administration to infants
ITMI20121041A1 (it) 2012-06-15 2013-12-16 Lga Biotecnologie S R L Chemioprevenzione del cancro del colon - retto
CN106109476A (zh) * 2016-06-13 2016-11-16 中山大学 骨化二醇作为吲哚胺2,3‑双加氧酶‑1抑制剂的用途

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5260067A (en) * 1988-11-16 1993-11-09 Xu Zheng Cytotropic heterogeneous molecular lipids (CHML) and process for preparing the same
US5798345A (en) * 1990-09-21 1998-08-25 Bone Care International, Inc. Method of inhibiting the hyperproliferation of malignant cells
US5486509A (en) * 1991-06-28 1996-01-23 University Of Miami Method of preventing and treating chemotherapy-induced alopecia
EP0619305B1 (en) * 1993-02-05 1997-06-04 Teijin Limited Lactone compound and process of producing thereof
AUPO727097A0 (en) * 1997-06-10 1997-07-03 Unisearch Limited Method of treatment of hepatoma and pharmaceutical compositions for use therein
CN1090180C (zh) * 1997-06-25 2002-09-04 帝人株式会社 维生素d3衍生物及其用于炎性呼吸道疾病的治疗剂

Also Published As

Publication number Publication date
WO1999056697A2 (en) 1999-11-11
WO1999056697A3 (en) 2001-06-21
EP1124557A4 (en) 2002-08-07
EP1124557A2 (en) 2001-08-22
US20020128239A1 (en) 2002-09-12
KR20010052305A (ko) 2001-06-25
HK1044117A1 (en) 2002-10-11
CN1332629A (zh) 2002-01-23
HK1044117B (zh) 2005-10-21
JP2002513733A (ja) 2002-05-14
US6664246B2 (en) 2003-12-16
ZA200006953B (en) 2002-03-28
AUPP332898A0 (en) 1998-05-28

Similar Documents

Publication Publication Date Title
US6448287B1 (en) Treatment of cancer using lipoic acid in combination with ascorbic acid
JP2681147B2 (ja) がん性腫瘍転移の治療剤
AU2017205337B2 (en) Formulations for treating bladder cancer
Cay et al. Inhibitory effect of 2-deoxy-D-glucose on liver tumor growth in rats
CN1204893C (zh) 药物组合物
WO2012104822A1 (en) Combinations comprising macitentan for the treatment of glioblastoma multiforme
WO2003007957A1 (en) Method and composition for treatment of cancer
AU765846B2 (en) Pharmaceutical composition
Keller et al. Growth inhibition of experimental non‐Hodgkin's lymphomas with the targeted cytotoxic somatostatin analogue AN‐238
EP2056839A1 (en) Combination approaches to cancer treatment
CN118750445A (zh) 一种肝脏特异性靶向纳米制剂和应用
JP2004346023A (ja) 前立腺癌の局所治療剤
AU2002318983A1 (en) Mathod and composition for treatment of cancer
Becerra The effects of mirex on biliary excretion of bile salts and phenolphthalein glucuronide in male rats
Savina The effects of perfusion rates and bile salts on the absorption clearance of iopanoic acid.
Medina-Velazquez Evaluation of the avidin/biotin-liposome system injected in pleural space and peritoneum for drug delivery to mediastinal lymph nodes
Priestman et al. 6 A randomised trial of aminoglutethimide (AG) versus medroxyprogesterone acetate (MPA) as second-line agents in advanced carcinoma of the breast
Van Veelen et al. 5 Oral high-dose medroxyprogesterone acetate (MPA) versus tamoxifen (TAM) in advanced breast cancer and cross-over effect
Beex et al. 4 Oral versus intramuscular (IM) administration of high doses of medroxyprogesterone acetate (MPA) in pretreated women with advanced breast cancer. A final analysis of a multicenter trial

Legal Events

Date Code Title Description
C06 Publication
C10 Entry into substantive examination
PB01 Publication
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
C19 Lapse of patent right due to non-payment of the annual fee
CF01 Termination of patent right due to non-payment of annual fee